Skip to content
Abridge logoAbridgeSan Francisco, USA
Website

Abridge in 2026: Revenue, Valuation, Funding, CEO

Curated by Khrystyna Oleksiienko · Published

Abridge is a healthcare AI company that turns doctor-patient conversations into clinical notes, billing codes and decision support. Founded in 2018 by cardiologist Shiv Rao, it is live at more than 300 US health systems and was last valued at a reported $5.3 billion in June 2025.

Company overview

Company
Abridge AI, Inc. (Delaware)
Industry
Healthcare AI: clinical documentation and clinician intelligence
Founded
2018
Headquarters
San Francisco, USA
Revenue
Not disclosed; $117M contracted ARR reported for Q1 2025
Funding stage
Series E at a reported $5.3B (Jun 2025); Eli Lilly strategic investment (Jun 2026)

Abridge’s last reported valuation is $5.3 billion, set in its June 2025 Series E. The healthcare AI company, founded in 2018 by cardiologist Shiv Rao, listens to doctor-patient conversations and drafts the clinical note. It is live at more than 300 US health systems and supports more than 100 million conversations a year, the company said in June 2026.

Abridge at a glance

Question

Answer

As of

Who owns Abridge?

It is private, held by its founders, staff and investors including a16z, Lightspeed, IVP, Elad Gil, Spark Capital and Union Square Ventures

Nov 2026

Valuation

$5.3 billion (reported)

Jun 2025

Funding

About $773 million in announced rounds; press reports say about $830 million

Jun 2026

Revenue

Not disclosed; $117 million in contracted ARR reported

Q1 2025

Customers

More than 300 US health systems

Nov 2026

Scale

More than 100 million conversations a year

Jun 2026

Employees

435

Apr 2026

CEO

Shiv Rao, MD, co-founder

Nov 2026

Founded

February 2018, by Shiv Rao and Sandeep Konam

2018

Headquarters

San Francisco, with a hub in New York and roots in Pittsburgh

Nov 2026

Legal entity

Abridge AI, Inc., a Delaware corporation

Nov 2026

Website

abridge.com

2026

What does Abridge do?

Abridge records the conversation between a clinician and a patient, with AI drafting the note inside the electronic health record for the clinician to review. It began there and now sells a wider platform to hospitals, which it calls clinician intelligence:

  • Clinical documentation: notes across specialties and languages, for doctors and, since a 2024 project with Mayo Clinic and Epic, nurses

  • Revenue cycle: billing and risk-adjustment codes captured during the visit, real-time prior authorization with Highmark and Availity, and pre-bill review of inpatient claims since September 2026

  • Abridge Assistant: clinical decision support since April 2026, drawing on NEJM and JAMA, and on Cochrane evidence through a Wiley deal of November 16, 2026

  • Care Signals, debuted with Kaiser Permanente in August 2026

  • Clinical trials: surfacing trial opportunities during the visit, in partnership with Eli Lilly

Abridge doesn’t publish prices on its website; health systems buy it through enterprise agreements.

Abridge in 2026: from notes to decisions and billing

Abridge went from more than 250 health systems in February 2026 to more than 300 by June. On June 11 it launched its clinician intelligence platform, said NVIDIA would help build a foundation model for clinical conversations, and took a strategic investment from Eli Lilly.

In September the US Department of Veterans Affairs selected Abridge under an enterprise contract, through a distribution partner. The contract has a $775.72 million ceiling over five years, but it is shared across all eligible vendors, so that isn’t Abridge’s revenue. Abridge already serves clinicians at more than 75 VA medical centers. In October it signed an enterprise-wide agreement with the University of Texas System, and in November it made the Abridge Assistant free for 108,000 clinicians at community health centers.

Abridge valuation: history over time

Abridge’s valuation rose more than sixfold in 16 months, from $850 million in February 2024 to a reported $5.3 billion in June 2025. Abridge’s own Series E announcement didn’t state a valuation. No higher price has been reported since, and Eli Lilly’s 2026 investment came with no disclosed valuation.

Date

Event

Valuation

Jun 2026

Eli Lilly strategic investment

Not disclosed

Jun 2025

Series E

$5.3B (reported)

Feb 2025

Series D

$2.75B post-money

Feb 2024

Series C

$850M

Abridge funding: how much has it raised?

About $773 million in announced rounds (our sum), counting the Series E at the $315.9 million an SEC filing shows sold; Abridge announced it as $300 million. Press reports in 2026 put the total at about $830 million. The amount of Eli Lilly’s investment isn’t disclosed.

Date

Round

Amount

Led by

Valuation

Jun 11, 2026

Strategic investment

Not disclosed

Eli Lilly

Not disclosed

Jun 24, 2025

Series E

$300M announced; $315.9M in the SEC filing

Andreessen Horowitz, with Khosla Ventures

$5.3B (reported)

Feb 17, 2025

Series D

$250M

Elad Gil, IVP

$2.75B

Feb 23, 2024

Series C

$150M

Lightspeed, with Redpoint

$850M

Oct 26, 2023

Series B

$30M

Spark Capital

Not disclosed

Aug 11, 2022

Series A-1

$12.5M

Wittington Ventures

Not disclosed

By Oct 2020

Seed and Series A

$15M

Union Square Ventures, UPMC

Not disclosed

Was there a $316 million Series E extension in 2026?

Probably not as new money. Fortune and others describe a $316 million extension closed in April 2026 at the same $5.3 billion. Abridge hasn’t announced one, and its latest SEC filing, from June 2025, already shows $315.9 million sold in the original Series E. The two numbers match, so the reported extension is most likely the same money.

What is Abridge’s revenue?

Abridge doesn’t publish its revenue, and no 2026 figure has been reported. The last public number is $117 million in contracted annual recurring revenue in the first quarter of 2025, reportedly. Contracted ARR counts every signed deal, including customers who aren’t live yet, so actual revenue at that time was lower. Abridge doesn’t disclose profit or margins.

Abridge revenue and ARR over timeBooked ARR figures, as each source reported them. Every figure is in the table below.
$0$50M$100M$150MOct 2024: $50M Booked ARROct 2024Mar 2025: $117M Booked ARR$117MMar 2025
Abridge revenue and ARR figures, newest first
DateFigureType
Mar 2025$117MBooked ARR
Oct 2024$50MBooked ARR

Abridge ARR (annual recurring revenue)

$117 million in contracted ARR in Q1 2025, reportedly. Abridge hasn’t confirmed an ARR figure, and customers have roughly doubled since then, from more than 150 health systems in June 2025 to more than 300 in June 2026.

Abridge MRR (monthly recurring revenue)

Abridge doesn’t publish MRR. $117 million in contracted ARR works out to about $9.75 million a month (our calculation), as of Q1 2025.

Who owns Abridge?

Abridge is private. It is held by its founders, employees and investors, and none of their stakes are public. Andreessen Horowitz led the latest priced round. Other backers include Khosla Ventures, Elad Gil, IVP, Lightspeed, Redpoint, Spark Capital, Union Square Ventures, Bessemer, CapitalG, NVIDIA’s NVentures and Wittington Ventures, plus healthcare investors CVS Health Ventures, Kaiser Permanente Ventures, Mayo Clinic, UPMC and Eli Lilly.

Its June 2025 SEC filing lists four directors: Shiv Rao, Andy Weissman of Union Square Ventures, Will Reed of Spark Capital and Sebastian Duesterhoeft of Lightspeed. Rao said in May 2026 that an IPO isn’t on his radar.

Abridge customers: which health systems use it?

More than 300 US health systems, from the largest academic centers to community health centers. Some of the biggest deals:

Customer

What was announced

Date

University of Texas System

Enterprise-wide agreement

Oct 8, 2026

US Department of Veterans Affairs

Selected under the VA enterprise contract; live at 75+ medical centers

Sep 22, 2026

WashU Medicine and BJC Health

Expanded to 4,000 clinicians

Sep 2, 2026

Northwestern Medicine

Enterprise-wide, all hospitals and care settings

Jun 11, 2026

UPMC

Enterprise-wide, more than 12,000 clinicians by 2026

Oct 16, 2025

Northwell Health

System-wide across 28 hospitals

Oct 14, 2025

Kaiser Permanente

Enterprise deployment; its evaluation was published in NEJM AI

Apr 2, 2025

Mayo Clinic

Enterprise-wide, starting with about 2,000 clinicians

Jan 14, 2025

Johns Hopkins Medicine

6,700 clinicians, six hospitals

Dec 18, 2024

KLAS, which rates healthcare software from customer interviews, ranked Abridge first for ambient AI in revenue cycle management for the second year running in February 2026.

Abridge competitors

The biggest threat is Epic, the health-records vendor Abridge plugs into. Abridge became the first partner in Epic’s Pals program in August 2023, but in February 2026 Epic released its own AI Charting tool, built into the record.

Rival

What it is

Latest dated fact

Epic

Health-records giant with built-in AI Charting

Released Feb 2026

Microsoft

Owns Nuance and DAX Copilot; the enterprise incumbent

Bought Nuance for $19.7B in 2022

Ambience Healthcare

AI documentation and coding

$243M Series C at $1.25B, Jul 2025

Suki

Ambient AI documentation

$90M Series E, Oct 2026

Nabla

Clinical AI assistant, 130+ healthcare organizations

$70M Series C, Jun 2025; $120M raised in all

OpenEvidence

Free AI search engine for doctors

A rival since Abridge added decision support in Apr 2026

Abridge lawsuits and privacy questions

Patients have sued Abridge customers in California, saying visits were recorded without consent. A proposed class action against Sharp HealthCare, filed on November 26, 2025, also claims Abridge inserted statements into charts saying patients had consented when they hadn’t. A second, filed on April 8, 2026 in federal court, targets Sutter Health and MemorialCare. These are allegations against the health systems, and we found no ruling in either case as of November 2026.

Who is the CEO of Abridge? Founders and leadership

Shiv Rao, MD, a practicing cardiologist at UPMC, is co-founder and CEO. He started Abridge in February 2018 with Sandeep Konam, a Carnegie Mellon robotics graduate who was its CTO at launch. Florian Metze, then a Carnegie Mellon research professor, is also credited as a co-founder and left in 2019.

Person

Role

Shiv Rao, MD

Co-founder and CEO; practicing cardiologist at UPMC

San Oo

Named chief technology officer in May 2026; previously at Slack and Notion

Sagar Sanghvi

Named Abridge’s first chief financial officer in January 2025

Zachary Lipton

Joined as chief scientific officer in February 2023 from Carnegie Mellon and Amazon AI

Tim Hwang

Named general counsel in August 2024

Tina Shah, MD

Named chief clinical officer in September 2023

Rao’s bio and contact routes: Abridge CEO Shiv Rao: email, LinkedIn and bio.

Where is Abridge based, and how many employees does it have?

San Francisco, with a second hub in New York. The company grew out of Pittsburgh, where Rao still lives and practices. Abridge had 435 employees in April 2026. Its legal entity, Abridge AI, Inc., is a Delaware corporation; its first SEC filing, in April 2018, used the earlier name intelligible.ai Inc.

Key events

Date

Event

Nov 16, 2026

Wiley deal brings Cochrane evidence to the Abridge Assistant

Nov 13, 2026

Assistant made free for 108,000 community health center clinicians

Oct 8, 2026

Enterprise-wide agreement with the University of Texas System

Sep 22, 2026

Selected under the VA enterprise contract

Jun 11, 2026

Clinician intelligence platform; Eli Lilly investment; NVIDIA model

May 21, 2026

San Oo named CTO

Apr 15, 2026

NEJM and JAMA content partnerships

Apr 8, 2026

Patients sue Sutter Health and MemorialCare over Abridge recordings

Feb 2026

Epic releases its own AI Charting tool

Nov 26, 2025

Proposed class action filed against Sharp HealthCare

Jun 24, 2025

$300M Series E, at a reported $5.3B

Feb 17, 2025

$250M Series D at $2.75B

Feb 23, 2024

$150M Series C at $850M

Aug 16, 2023

Becomes the first Pal in Epic’s partner program

Aug 11, 2022

$12.5M Series A-1 and an enterprise product for health systems

Oct 6, 2020

Launches publicly as an app for patients

Feb 2018

Founded by Shiv Rao and Sandeep Konam

More on Abridge

Need verified CEO emails for outbound? The LeadWave AI companies email list has verified emails of the CEOs and founders of 9,000+ AI companies.

Knowledge graph

Everything LeadWave has on Abridge: its leaders, our pages on it and the lists it’s on.

In this dossier

Frequently asked questions

More company dossiers

All dossiers
  • Bending Spoons logo

    Bending Spoons

    Bending Spoons in 2026: Revenue, Valuation, Funding, CEO

    Bending Spoons is a Milan software company, listed on Nasdaq as BSP since July 1, 2026, that buys and rebuilds digital businesses such as Evernote, Vimeo, AOL, Airtable and Miro. It made $780 million in revenue in Q3 2026, was worth about $27 billion on November 20, 2026, and has agreed to buy Mailchimp for $3.68 billion.

    Read
  • Clio logo

    Clio

    Clio in 2026: Revenue, Valuation, Funding, CEO

    Clio is a Canadian legal software company that runs law firms’ cases, billing and payments and, since buying vLex for $1 billion in November 2025, legal research and AI. It passed $500 million in ARR in May 2026 and was valued at $5 billion in its November 2025 Series G.

    Read
  • Fireworks AI logo

    Fireworks AI

    Fireworks AI in 2026: Revenue, Valuation, Funding, CEO

    Fireworks AI runs and customizes open-source AI models for companies such as Uber, Shopify and Samsung. Founded in 2022 by seven engineers, led by PyTorch’s former head Lin Qiao, it passed $1 billion in annualized revenue in July 2026 and was valued at $17.5 billion, with talks reported in October at up to $40 billion.

    Read
  • Mailchimp logo

    Mailchimp

    Mailchimp in 2026: Revenue, Valuation, Funding, CEO

    Mailchimp made $1.27 billion in revenue in Intuit’s fiscal 2026. On November 19, 2026 Intuit agreed to sell it to Bending Spoons at a $3.68 billion enterprise value, less than a third of the $12 billion it paid in 2021. Intuit owns Mailchimp until the sale closes, expected in early 2027.

    Read
  • Replit logo

    Replit

    Replit in 2026: Revenue, Valuation, Funding, CEO

    Replit is an AI platform that builds, hosts and runs apps from plain-English prompts. It was valued at $9 billion in a $400 million Series D in March 2026 and says it is on track for $1 billion in run-rate revenue by the end of 2026.

    Read
  • Supabase logo

    Supabase

    Supabase in 2026: Revenue, Valuation, Funding, CEO

    Supabase is an open-source Postgres backend used by more than 13 million developers and by AI app builders such as Lovable. Founded in 2020 by Paul Copplestone and Ant Wilson, it was valued at $10.5 billion in June 2026 and raised another $150 million that October.

    Read